The miR-362-3p/BCLAF1 axis regulates cisplatin sensitivity and metastatic progression in triple-negative breast cancer
Liu, Z.; Wu, C.; Uyemura, M.; Sardella, B. R.; Aronson, E. K.; Ke, S.; Massicott, E. S.; Li, X.; Wang, L.; Karagkouni, D.; Kalavros, N.; Vlachos, I. S.; Batalini, F.; Bogsan, C. S.; Cheong, J. K.; Zhou, L.; Cheng, H.; Munson, P.; Mayer, E. L.; Garber, J. E.; Schnitt, S. J.; Tung, N. M.; Kasinski, A. L.; Frank, S. J.; Wulf, G. M.; Heng, Y. J.
Show abstract
Platinum-based chemotherapy remains a cornerstone of treatment for triple-negative breast cancer (TNBC), yet the molecular determinants governing platinum response remain poorly defined. By leveraging the randomized Phase II INFORM trial, which compared neoadjuvant cisplatin to anthracycline-based therapy in BRCA1/2-mutant breast cancer--we identified miR-362-3p as a specific regulator of cisplatin sensitivity. Higher plasma miR-362-3p expression was exclusively associated with favorable clinical outcome in the cisplatin arm, with no association observed in the AC arm, decoupling platinum-specific vulnerability from general chemotherapy response. We used gain- and loss-of-function TNBC models to establish that miR-362-3p functions as a potent sensitizer to cisplatin in vitro and in vivo. Integrated TCGA analysis and experimental validation identified BCLAF1, a key regulator of DNA damage response, as a direct repression target of miR-362-3p. We uncovered a novel role for the miR-362-3p/BCLAF1 axis in overcoming platinum resistance in TNBC.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Propagated circulating tumor cells uncovers the rople of NFκB and COP1 in metastasis 96%
- The epithelial-mesenchymal transcription factor SNAI1 represses transcription of the tumor suppressor miRNA let-7 in cancer 95%
- The French Early Breast Cancer Cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS) 95%
Similar papers in this journal
- RNA Sequencing-Based Single Sample Predictors of Molecular Subtype and Risk of Recurrence for Clinical Assessment of Early-Stage Breast Cancer 95%
- Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors 95%
- The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer 95%
Similar papers in this journal
Similar papers in this journal
- Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy 96%
- Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences 96%
- Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity 96%
Similar papers in this journal
- CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis 96%
- Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts 95%
- Pharmacologically targeting KRASG12D in PDAC models:tumor cell intrinsic and extrinsic impact 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.